WallStSmart

Abbott Laboratories (ABT)vsMaxCyte Inc (MXCT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Abbott Laboratories generates 136562% more annual revenue ($45.13B vs $33.03M). ABT leads profitability with a 13.9% profit margin vs -135.1%. ABT earns a higher WallStSmart Score of 56/100 (C).

ABT

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 6.0Quality: 4.8
Piotroski: 3/9

MXCT

Avoid

30

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 8.0
Piotroski: 2/9Altman Z: 2.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ABTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$87.55

Current Price

$84.32

$3.23 discount

UndervaluedFair: $87.55Overvalued
MXCTUndervalued (+44.7%)

Margin of Safety

+44.7%

Fair Value

$1.32

Current Price

$0.84

$0.48 discount

UndervaluedFair: $1.32Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ABT2 strengths · Avg: 8.5/10
Market CapQuality
$151.56B9/10

Large-cap with strong market position

Price/BookValuation
2.8x8/10

Reasonable price relative to book value

MXCT2 strengths · Avg: 9.5/10
Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

ABT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-19.7%2/10

Earnings declined 19.7%

MXCT4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$90.34M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-23.6%2/10

ROE of -23.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : ABT

The strongest argument for ABT centers on Market Cap, Price/Book. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : MXCT

The strongest argument for MXCT centers on Price/Book, Debt/Equity.

Bear Case : ABT

The primary concerns for ABT are Piotroski F-Score, EPS Growth.

Bear Case : MXCT

The primary concerns for MXCT are EPS Growth, Market Cap, Piotroski F-Score.

Key Dynamics to Monitor

ABT profiles as a value stock while MXCT is a turnaround play — different risk/reward profiles.

MXCT carries more volatility with a beta of 1.57 — expect wider price swings.

ABT is growing revenue faster at 7.8% — sustainability is the question.

ABT generates stronger free cash flow (916M), providing more financial flexibility.

Bottom Line

ABT scores higher overall (56/100 vs 30/100). MXCT offers better value entry with a 44.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Abbott Laboratories

HEALTHCARE · MEDICAL DEVICES · USA

Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.

Visit Website →

MaxCyte Inc

HEALTHCARE · MEDICAL DEVICES · USA

MaxCyte Inc. (MXCT) is a pioneering company in the field of cell-engineering, distinguished by its innovative Flow Electroporation® technology, which facilitates the efficient and scalable introduction of nucleic acids and proteins into various cell types. Serving a diverse clientele that includes leading biopharmaceutical companies and prominent research institutions, MaxCyte is strategically positioned in the burgeoning cell and gene therapy market. The company's cutting-edge platforms are integral to the development of novel cell-based therapies and vaccines, allowing it to seize substantial growth opportunities within the healthcare landscape. Committed to advancing transformative medical solutions, MaxCyte is set to meet the increasing global demand for innovative therapeutic approaches.

Visit Website →

Want to dig deeper into these stocks?